KYAN Technologies is leading the way in functional precision medicine, revolutionizing cancer care through the strategic use of advanced technology and expertise. Our devoted team aims to bridge the gap in cancer care by integrating small data AI and biological experiments to develop a truly personalized solution.
Our cutting-edge platform solution, Optim.AI™, empowers healthcare providers and scientists to make informed clinical and research decisions. This powerful tool provides critical insights, supporting healthcare providers and patients alike.
Our primary objective at KYAN is to enhance drug development and delivery, developing novel biopharmaceutical assets and expanding drug use. We are committed to providing better treatment options to as many patients as possible.
In addition to our groundbreaking technology, KYAN is committed to conducting extensive research studies across various cancer indications, including Colorectal and Breast Cancer. These studies not only contribute to the advancement of biopharma services but also aid in the development of novel biopharmaceutical assets.
Our ex vivo analytic platform, Optim.AI™, empowers oncologists to better guide treatment for patients with truly personalized results